Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data PRECISION BIOSCIENCES INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
10.9
1,070
24.3
116
25.1
48.7
68.7
34.3
Research and development
45.1
82.4
98.1
115
46.1
53.4
59.6
54.2
General and administrative
13.7
27
36.1
39.7
41.3
39.1
35.3
32.2
Operating expenses
58.8
109
134
155
87.4
92.5
94.9
86.4
Operating income
-47.9
-87.2
-110
-39.4
-62.3
-43.7
-26.2
-52.1
Interest expense
0.18
0.13
1.11
2.23
1.78
1.42
Interest income
1.88
4.27
0.82
0.21
3.47
7.69
6.76
4.24
Other non-operating income
1.88
-5.67
0.82
8.77
-10.6
1.21
33.3
5.54
Pre-tax income
7.17
-45.7
Income tax
0.02
0
0
Income from continuing operations
-72.9
-42.5
7.17
-46.6
Net income
-46
-92.9
-109
-30.6
-112
-61.3
7.17
-45.7
EBITDA
-45.6
-81.9
-101
-30.4
-54.5
-36.9
-22.8
-50.7
EPS, basic
-87.60
-66.30
-62.70
-15.60
-38.10
-15.96
1.05
-3.56
EPS, diluted
-87.60
-66.30
-62.70
-15.60
-38.10
-15.96
1.04
-3.56
Shares, basic (weighted)
0.53
1.4
1.73
1.96
2.93
3.84
6.83
12.8
Shares, diluted (weighted)
0.53
1.4
1.73
1.96
2.93
3.84
6.88
12.8
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
103
181
89.8
144
190
117
85.9
111
Short-term investments
0.41
4.76
Receivables
0.52
0.97
10
0.49
0.72
0.9
0.23
0
Other current assets
3.05
2.32
0
0.17
1.23
0.42
0.37
0.05
Total current assets
116
194
106
162
199
136
95
119
Property, plant and equipment
21.1
39.6
35.1
25.2
11.8
6.34
3.09
1.43
Lease right-of-use assets
6.41
4.18
1.96
8.26
7.09
5.81
Intangible assets
1.47
1.43
1.37
2.05
0.73
0.4
0.62
1.17
Other non-current assets
0.31
0.56
1.72
4.64
0.23
0.23
0.22
0.21
Total assets
139
235
150
211
238
160
136
154
Accounts payable
2.22
2.04
0.79
1.14
0.65
2.97
1.31
0.3
Accrued liabilities
0.97
4.43
5.75
6.77
5.1
4.98
5.18
4.75
Deferred revenue
8.44
16.5
30.2
21.2
46.2
12
2.96
0
Total current liabilities
14.1
26.9
42.8
36
59.7
50
15
8.91
Lease liabilities
8.59
4.81
1.06
7.72
6.4
4.9
Other non-current liabilities
0.39
0.04
0.2
0.13
0.19
0.26
Total liabilities
98.6
96.9
106
120
178
141
80
62.2
Total debt
2.48
22.2
Paid-in capital
126
316
331
409
490
509
540
621
Retained earnings
-85.2
-177
-286
-317
-428
-490
-482
-528
Treasury stock
-0.95
-0.95
-0.95
-0.95
-0.95
-0.95
-0.95
-0.95
Shareholders' equity
40
138
44.4
91.2
60.4
18.9
56.4
92.2
Total equity
40
138
44.4
91.2
60.4
18.9
56.4
92.2
Total liabilities and equity
139
235
150
211
238
160
136
154
Shares outstanding
0.53
1.71
1.76
2.03
3.7
4.16
8.2
24.1
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-46
-92.9
-109
-30.6
-112
-61.3
7.17
-45.7
Depreciation and amortization
2.35
5.32
8.78
8.98
7.8
6.82
3.4
1.47
Stock-based compensation
2.45
8.94
13.8
16.5
19.2
14
12.6
10.2
Change in receivables
-0.52
-0.44
-9.04
9.51
-0.23
-0.18
0.67
0.23
Change in payables
-0.67
0.67
-1.46
0.87
0.15
1.51
-2.1
-0.74
Cash from operations
-51.7
-71
-87.4
-10.9
-45.8
-84.1
-58.4
-65.8
Capital expenditures
-14.3
-24.7
-5.03
-5.05
-3.32
-1.96
-0.25
-0.09
Cash from investing
-15.7
-24.7
-5.03
-5.8
-3.32
5.83
-0.22
-0.63
Debt repaid
-2.5
Stock issued
0.17
1.26
0.69
25.5
49.3
4.99
Cash from financing
108
173
1.33
70.5
95
5.39
50.5
95.2
Net change in cash
40.4
77.7
-91.1
53.9
45.9
-72.9
-8.21
28.7
Free cash flow
-66
-95.7
-92.4
-15.9
-49.1
-86.1
-58.7
-65.9
Interest paid
0.07
0.82
2.02
1.74
1.36
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.22 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-80.8%
Operating income / revenue.
EBITDA margin
-78.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-117.0%
Net income / revenue.
FCF margin
-115.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-115.2%
Cash from operations / revenue.
Return on equity (ROE)
-116.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-41.9%
Net income / average total assets.
R&D / revenue
118.3%
Research and development expense / revenue.
Stock-based pay / revenue
17.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
2.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-50.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
10.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
7.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y
-738.0%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-442.3%
EPS vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
63.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
15.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
15.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
13.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
0.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
86.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
63.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
49.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.8x
Current assets / current liabilities.
Quick ratio
12.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
12.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.74
Revenue / diluted weighted shares.
FCF per share
-$2.01
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.01
Cash from operations / diluted weighted shares.
Book value per share
$1.71
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
3.81x
Market cap / revenue.
P/B
3.79x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.88x
Market cap / tangible book value, when positive.
EV/Sales
1.87x
Enterprise value / revenue.
FCF yield
-30.3%
Free cash flow / market cap.
Earnings yield
-30.7%
Net income / market cap (the inverse of P/E).
What was PRECISION BIOSCIENCES INC's revenue in fiscal 2025?
PRECISION BIOSCIENCES INC reported revenue of $34.3M for fiscal 2025, 50.1% lower than the year before.
Was PRECISION BIOSCIENCES INC profitable in fiscal 2025?
No. It reported a net loss of $45.7M.
How much free cash flow did PRECISION BIOSCIENCES INC generate in fiscal 2025?
Cash from operations of $65.8M minus capital expenditures of $85.0K left free cash flow of -$65.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.